Table 1.
Patient demographics and clinical features.
| Patients | Age (Years) | Sex | Past History | Location and Details of Dermal Filler Injections | Type of Dermal Filler | Overall Follow-Up (Days) | Day of Dermal Filler Injection before Admission |
|---|---|---|---|---|---|---|---|
| Patient 1 | 40 | F | Two NLF rejuvenations with PLLA in the past 3 years | NLF R/L 1 mL/1 mL (with 23-G cannula) | HA | 14 | D2 |
| Patient 2 | 25 | F | Nil | Nasal tip 0.3 mL/dorsum 0.3 mL/radix 0.3 mL/chin 0.6 mL (with 27-G needle) | CaHA | 24 | D4 |
| Patient 3 | 31 | F | Open rhinoplasty and septal reconstruction 1 year ago | NLF R/L 1 mL/1 mL (with 25-G cannula) | HA | 53 | D0 (6 h) |
| Patient 4 | 42 | F | Nil | Nasal tip 0.2 mL/dorsum 0.1 mL (with 27-G needle) | HA | 11 | D4 |
| Patient 5 | 45 | F | Nil | Upper and lower lips 1 mL (with 27-G needle) | HA | 13 | D1 |
| Patient 6 | 25 | M | Nil | Acne scar treatment (multiple sites involving bilateral cheeks): Subcision followed-by HA injection (with 27-G needle): 1 mL totally | HA | 20 | D6 |
| Patient 7 | 43 | F | Close rhinoplasty with prosthesis | Nose augmentation 2 c.c. (with 27-G needle) | HA | 13 | D3 |
| Patient 8 | 33 | F | Nil | Bilateral NLF R/L: 1.6 c.c./0.4 c.c. (with 27-G needle) |
HA | 12 | D0 (6 h) |
| Patient 9 | 61 | F | Nil | Nasal tip 0.8 c.c. (with 27-G cannula) |
HA | 100 | D6 |
| Patient 10 | 23 | F | Nil | Bilateral forehead and temporal fossa R/L: 3 c.c./3 c.c. (with 21-G cannula) |
HA | 10 | D2 |
| Patient 11 | 43 | F | Nil | Bilateral NLF R/L: 0.4 c.c./0.4 c.c. Left tear trough: 0.3 c.c. (with 21-G cannula) |
HA | 28 | D1 |
| Patient 12 | 29 | F | Nil | Bilateral NLF R/L: 0.4 c.c./0.4 c.c. (with 27-G needle) |
HA | 12 | D1 |
| Patient 13 | 47 | F | Nil | Bilateral NLF R/L: HA 1 c.c./1 c.c. (with 22-G cannula) |
HA | 12 | D2 |
CaHA, calcium hydroxylapatite; D, Day; F and M, female and male, respectively; HA, hyaluronic acid; NLF, nasolabial fold; OPD, outpatient department; PLLA, poly-L-lactic acid; R and L: right and left, respectively.